Latest filing published 17 Mar 2025 for Mineralys Therapeutics, Inc., €7.4M.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 7 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +54.9%Entry US$15.43 · Close at T+365 US$23.90
- -17.1%Entry US$25.43 · Close at T+365 US$21.08
- -31.6%Entry US$14.98 · Close at T+365 US$10.24
- +307.3%Entry US$7.50 · Close at T+365 US$30.55
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Samsara BioCapital GP, LLC: trading record in brief
Filings by Samsara BioCapital GP, LLC span 5 companies, the busiest being Neurogene Inc., CARGO Therapeutics, Inc. and Mineralys Therapeutics, Inc. We count 11 filings; the first trade dates from 16 October 2023 and the latest from 13 March 2025.
The open-market record is one-sided, with 9 purchases worth €43.8M and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2025 to date brings 1 purchase and no sales.
A typical purchase (the median) is worth €4.6M. On 7 out of 9 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. After 7 purchases with a full 90-day history, the hit rate stands at 14% and the median 90-day move at -32.4%. Past outcomes like these are no guarantee of what comes next.
On 17 March 2025 came the latest disclosure, an open-market purchase for €7.4M in Mineralys Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Samsara BioCapital GP, LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 600,000 shares@ US$13.5051.7% of flowCommon StockSEC:0001415889-25-008275:0Canonical exit: 11 Jun 2025 (T+90)
- 58,836 sharesClass A Common StockSEC:0001415889-24-028465:0
- 20,748 shares@ US$24.91100.0% of flowCommon StockSEC:0001415889-24-027861:0Canonical exit: 24 Feb 2025 (T+90)
- 10,803 shares@ US$26.0122.3% of flowCommon StockSEC:0001415889-24-027861:1Canonical exit: 24 Feb 2025 (T+90)
- 15,219 shares@ US$26.7332.3% of flowCommon StockSEC:0001415889-24-027861:2Canonical exit: 24 Feb 2025 (T+90)
- 2,000 shares@ US$27.504.4% of flowCommon StockSEC:0001415889-24-027861:3Canonical exit: 24 Feb 2025 (T+90)
- 294,000 shares@ US$17.00100.0% of flowCommon StockSEC:0001415889-24-015250:0Canonical exit: 28 Aug 2024 (T+90)
- 555,555 shares@ US$13.5048.3% of flowCommon StockSEC:0001415889-24-003859:0Canonical exit: 12 May 2024 (T+90)
- 666,666 shares@ US$15.0067.0% of flowCommon StockSEC:0001209191-23-055621:1Canonical exit: 12 Feb 2024 (T+90)
- 3,381,323 sharesCommon StockSEC:0001209191-23-055621:0
- 2,189,781 shares@ US$6.85100.0% of flowCommon StockSEC:0001209191-23-053111:0Canonical exit: 14 Jan 2024 (T+90)
11 of 11 declarations